LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.
Company profile
Ticker
LMAT
Exchange
Website
CEO
George LeMaitre
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
LeMaitre Vascular GmbH • LeMaitre Acquisition LLC • LeMaitre Vascular SAS • LeMaitre Vascular Spain, S.L. • LeMaitre Vascular S.r.l. • Vascutech Acquisition LLC • LeMaitre Vascular ULC • LeMaitre Vascular Switzerland GmbH • LeMaitre Vascular Pty Ltd • LeMaitre Medical Technology (Shanghai) Co., Ltd. ...
LMAT stock data
Latest filings (excl ownership)
10-K
2022 FY
Annual report
1 Mar 23
8-K
LeMaitre Q4 2022 Financial Results
23 Feb 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
LeMaitre Q3 2022 Financial Results
27 Oct 22
8-K
Departure of Directors or Certain Officers
23 Sep 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
8-K
LeMaitre Q2 2022 Financial Results
28 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
3 Jun 22
SD
Conflict minerals disclosure
31 May 22
10-Q
2022 Q1
Quarterly report
10 May 22
Transcripts
LMAT
Earnings call transcript
2022 Q4
23 Feb 23
LMAT
Earnings call transcript
2022 Q3
28 Oct 22
LMAT
Earnings call transcript
2022 Q2
30 Jul 22
LMAT
Earnings call transcript
2022 Q1
30 Apr 22
LMAT
Earnings call transcript
2021 Q4
25 Feb 22
LMAT
Earnings call transcript
2021 Q3
29 Oct 21
LMAT
Earnings call transcript
2021 Q2
31 Jul 21
LMAT
Earnings call transcript
2021 Q1
2 May 21
LMAT
Earnings call transcript
2020 Q4
28 Feb 21
LMAT
Earnings call transcript
2020 Q3
1 Nov 20
Latest ownership filings
4
Trent G Kamke
8 Mar 23
4
Trent G Kamke
6 Mar 23
4
Lawrence J Jasinski
6 Mar 23
4
David B Roberts
1 Mar 23
4
Bridget A Ross
1 Mar 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13G/A
LeMaitre George W
31 Jan 23
SC 13G/A
BlackRock Inc.
26 Jan 23
5
John James O'Connor
25 Jan 23
SC 13G
BlackRock Inc.
20 Jan 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q4 2022
86.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 181 |
| Opened positions | 20 |
| Closed positions | 26 |
| Increased positions | 62 |
| Reduced positions | 65 |
| 13F shares | Current |
|---|---|
| Total value | 764.87 bn |
| Total shares | 19.03 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 3.28 mm | $151.16 bn |
| Conestoga Capital Advisors | 1.84 mm | $84.75 bn |
| Vanguard | 1.48 mm | $68.00 bn |
| Copeland Capital Management | 1.28 mm | $58.79 mm |
| Ranger Investment Management | 948.48 k | $43.65 bn |
| Geneva Capital Management | 893.31 k | $41.11 bn |
| STT State Street | 736.55 k | $33.90 bn |
| Dimensional Fund Advisors | 667.90 k | $30.74 mm |
| Cramer Rosenthal MCGLYNN | 463.63 k | $21.34 bn |
| Geode Capital Management | 396.91 k | $18.37 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Mar 23 | Kamke Trent G | Common Stock | Option exercise | Acquire M | No | No | 35.48 | 81 | 2.87 k | 7,298 |
| 7 Mar 23 | Kamke Trent G | Common Stock | Option exercise | Acquire M | No | No | 23.56 | 2,008 | 47.31 k | 7,217 |
| 7 Mar 23 | Kamke Trent G | Common Stock | Option exercise | Acquire M | No | No | 31.3 | 1,592 | 49.83 k | 5,209 |
| 7 Mar 23 | Kamke Trent G | Stock Option Common Stock | Option exercise | Dispose M | No | No | 35.48 | 81 | 2.87 k | 5,331 |
| 7 Mar 23 | Kamke Trent G | Stock Option Common Stock | Option exercise | Dispose M | No | No | 23.56 | 2,008 | 47.31 k | 4,018 |
| 3 Mar 23 | Kamke Trent G | Common Stock | Sell | Dispose S | No | No | 50.9416 | 6,414 | 326.74 k | 3,791 |
| 2 Mar 23 | Jasinski Lawrence J | Common Stock | Sell | Dispose S | No | No | 50 | 192 | 9.60 k | 9,310 |
| 27 Feb 23 | Roberts David B | Common Stock | Sell | Dispose S | No | No | 49.39 | 11,503 | 568.13 k | 19,937 |
| 27 Feb 23 | Roberts David B | Common Stock | Sell | Dispose S | No | No | 50.27 | 1,700 | 85.46 k | 31,440 |
| 27 Feb 23 | Roberts David B | Common Stock | Sell | Dispose S | No | No | 51.31 | 905 | 46.44 k | 33,140 |
News
Lemaitre Vascular Announced That It Has Signed A Definitive Agreement To Buy Out Its Thai Distributor, Prompt Serve, For $688,000
14 Mar 23
LeMaitre Vascular Sees FY23 EPS $1.11-$1.20 Vs $1.19 Est.; FY23 Revenue $174.3M-$178.3M Vs $171.3M Est
23 Feb 23
LeMaitre Vascular Sees Q1 EPS $0.22-$0.27 Vs $0.26 Est; Q1 Revenue $42.6M-$45M Vs $40.93M Est
23 Feb 23
LeMaitre Vascular Q4 EPS $0.25 Misses $0.26 Estimate, Sales $41.00M Beat $40.99M Estimate
23 Feb 23
Earnings Scheduled For February 23, 2023
23 Feb 23